The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market

Project Information

ArtOfHeart

Grant agreement ID: 190157517

DOI 10.3030/190157517

EC signature date 1 August 2022

Start date 1 April 2022

End date 31 March 2026

Funded under

• The European Innovation Council (EIC)

Total cost € 38 241 965,75

EU contribution € 2 500 000,00

Coordinated by

SCANDINAVIAN REAL HEART AB
Sweden

Project description

New easy-to-implant artificial heart

The heart delivers blood to the rest of the body through a network of arteries and veins. If the heart is failing and other treatments are not effective, a transplant is necessary. Unfortunately, the waiting times for heart transplants are long. In this context, the European Innovation Council ArtOfHeart project will develop an artificial heart that can serve as a permanent solution for patients waiting for a transplant, as well as end-stage heart failure patients. The heart is designed to mimic the structure and function of the human heart. It is easy to implant, automatically adapts to different (physiological) activity levels and it has a 12-hour battery. It consists of two identical artificial heart pumps, a drive line and an intelligent control unit.

Objective

The Realheart TAH system (RTS) is the first total artificial heart designed to mimic the structure and function of the human heart. Its unique patented construction of two atria and two ventricles is separated by an atrioventricular plane which contains the valves, enabling to pump blood naturally whilst reducing the risk of blood flow complications. RTS is designed to be efficient (12h battery), silent, lightweight (2.5kg) easy to implant and automatically adapt to different (physiological) activity levels. It consists of two identical artificial heart pumps, a drive line and an intelligent control unit. RTS is connected via a cable through the skin to a controller carried together with two batteries in a belt around the waist. RTS is aimed as a permanent solution for end-stage heart failure patients, but also for patients waiting for a transplant. Realheart will complete GLP animal trial, clinical trial preparatory activities and first-in-man (EFS) trial during the EIC project.

Fields of science

• medical and health sciences › clinical medicine › cardiology
• medical and health sciences › medical biotechnology › implants

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
• HORIZON.3.1.2 - The Accelerator

Topic(s)

• HORIZON-EIC-2021-ACCELERATOROPEN-01 - EIC Accelerator Open 2021

Call for proposal

HORIZON-EIC-2021-ACCELERATOROPEN-01

Funding Scheme

HORIZON-AG - HORIZON Action Grant Budget-Based

Coordinator

SCANDINAVIAN REAL HEART AB

• Net EU contribution: € 2 500 000,00
• Address: KOPPARBERGSVAGEN 10 ; 722 13 VASTERAS ; Sweden
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Östra Sverige › Östra Mellansverige › Västmanlands län
• Region: Östra Sverige › Östra Mellansverige › Västmanlands län
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 38 241 965,75